Pneumococcal vaccination in at-risk adults: Assessing targets and benefits
At the recent Pfizer webinar “Pneumococcal Vaccination in High-Risk Individuals: Are We Doing It Right?”, Dr Petrick Periyasamy, head of the Hospital Canselor Tuanku Muhriz UKM Infectious Diseases Unit, discussed the currently known epidemiology of adult pneumococcal disease (PD),as well as the impact of vaccines on PD prevention in at-risk populations.

New Molecule

3 New

New Indication

5 New

New Brand

2 New

Markings
Shape
Form
Color 1
Color 2
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in